九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

603456 九洲药业

交易中 11-19 13:21:03

{"stockData":{"symbol":"603456","market":"SH","secType":"STK","nameCN":"九洲药业","latestPrice":15.17,"timestamp":1731993663000,"preClose":15.15,"halted":0,"volume":8753815,"delay":0,"floatShares":894999999,"shares":894999999,"eps":0.7765,"marketStatus":"交易中","marketStatusCode":2,"change":0.02,"latestTime":"11-19 13:21:03","open":15.21,"high":15.36,"low":15.08,"amount":133000000,"amplitude":0.0185,"askPrice":15.17,"askSize":151,"bidPrice":15.16,"bidSize":55,"shortable":0,"etf":0,"ttmEps":0.7765,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1731999600000},"adr":0,"adjPreClose":15.15,"symbolType":"stock","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":16.67,"lowLimit":13.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":898106828,"pbRate":1.59,"roa":"--","roe":"7.4%","epsLYR":1.16,"committee":-0.170691,"marketValue":13581000000,"floatMarketCap":13581000000,"peRate":19.536382,"changeRate":0.0013,"turnoverRate":0.0098,"status":0},"requestUrl":"/m/hq/s/603456/tweets","defaultTab":"tweets","newsList":[{"id":"2484649419","title":"九洲药业拟注销287万股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2484649419","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484649419?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:35","pubTimestamp":1731922500,"startTime":"0","endTime":"0","summary":"财中社11月18日电九洲药业（603456）发布关于注销部分已回购股份的实施公告。公司决定将2022年股份回购方案的用途由“用于后续实施股权激励计划”变更为“用于注销并减少公司注册资本”，因此将回购专用证券账户中的287万股库存股进行注销。本次注销股份的数量占公司目前总股本的0.32%。注销后，公司总股本将由8.98亿股减少至8.95亿股。此次注销将于2024年11月19日进行，并及时办理注册资本变更登记手续。公司表示此举旨在提高股东的投资回报，增强投资者信心。2024年前三季度，九洲药业实现收入39.65亿元，归母净利润6.31亿元。（文章来源：财中社）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118174124abcc2683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118174124abcc2683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"hk","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["NVO","BK0251","BK0070","BK0012","LU0405327148.USD","01801","BK4007","BK0028","BK0183","LU1328615791.USD","BK4585","BK0060","600276","BK0113","BK0201","BK0114","LU2148510915.USD","LU0154236417.USD","688076","BK0042","LU1093756168.USD","LU1064131003.USD","002821","300003","BK0132","BK0196","LU1093756325.SGD","603456","LU0405327494.USD","IE00BKVL7J92.USD","BK0239","LU2488822045.USD","LU1064130708.USD","300199","BK0077","IE00BZ1G4Q59.USD","BK0188","BK4532","BK4588","688117"],"gpt_icon":1},{"id":"2483582796","title":"九洲药业获得实用新型专利授权：“一种高盐高浓废水收集池的回流搅拌装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2483582796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483582796?lang=zh_cn&edition=full","pubTime":"2024-11-16 03:46","pubTimestamp":1731700005,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示九洲药业新获得一项实用新型专利授权，专利名为“一种高盐高浓废水收集池的回流搅拌装置”，专利申请号为CN202420635715.3，授权日为2024年11月15日。本实用新型在废水收集池的不同位置、方向和深度布置多个回流点，有效提高回流搅拌混合效果，使收集池内的废水混的更加均匀、充分，且有效提高了装置检修、维护的便捷性和运行的安全性。今年以来九洲药业新获得专利授权8个，与去年同期持平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111600010577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2483079557","title":"九洲药业：公司今年已完成一轮股份回购，公司董事、高级管理人员也已完成增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2483079557","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483079557?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:00","pubTimestamp":1731492041,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)11月13日在投资者关系平台上答复投资者关心的问题。投资者：公司有提振股价的措施吗？业绩重新步入增长还要多久？九洲药业董秘：您好，感谢您对公司的关注与支持，公司今年已完成一轮股份回购，公司董事、高级管理人员也已完成增持计划。同时为增强投资者信心，公司准备注销2022年股份回购方案中的库存股，公司将持续聚焦主营业务，推动公司业务可持续增长。谢谢！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300030153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2483302538","title":"九洲药业11月13日主力资金流出3357万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483302538","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483302538?lang=zh_cn&edition=full","pubTime":"2024-11-13 15:20","pubTimestamp":1731482439,"startTime":"0","endTime":"0","summary":"11月13日, 九洲药业股价跌1.82%，报收16.19元，成交金额3.61亿元，换手率2.49%，振幅4.12%，量比0.78。九洲药业今日主力资金净流出3357万元，连续3日净流出，上一交易日主力净流出7366万元，今日环比减少54.43%。该股近5个交易日上涨0.68%，主力资金累计净流出1.16亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出2891万元，其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113153427abbc7776&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113153427abbc7776&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2482721489","title":"九洲药业11月12日遭主力抛售7366万元 环比增加507.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482721489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482721489?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:22","pubTimestamp":1731396146,"startTime":"0","endTime":"0","summary":"11月12日, 九洲药业股价跌0.84%，报收16.49元，成交金额5.90亿元，换手率3.92%，振幅4.81%，量比1.32。九洲药业今日主力资金净流出7366万元，上一交易日主力净流出1212万元，今日环比增加507.76%。净流出前三个股分别为九洲药业、康龙化成、美年健康。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155734abb91a59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112155734abb91a59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0239","603456"],"gpt_icon":0},{"id":"2480017591","title":"九洲药业大跌5.08% 7家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2480017591","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480017591?lang=zh_cn&edition=full","pubTime":"2024-11-01 10:05","pubTimestamp":1730426736,"startTime":"0","endTime":"0","summary":"11月01日，九洲药业股价大幅下跌，截至10点05分，九洲药业下跌5.08%，报15.51元/股，成交2.61亿元，换手率1.85%，振幅3.12%。此外，数据统计显示，近半年内7家券商给予增持建议，10家券商给予买入建议。资金动向截止发稿，九洲药业获得主力净流出4136万元，其中超大单流出3174万元，大单流出960万元。最新财报显示，今年三季报，九洲药业实现营业收入39.65亿元，同比减少13.36%，净利润为6.31亿元，同比减少34.74%，基本每股收益为0.70元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101101107ab8ef3a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101101107ab8ef3a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2479719207","title":"九洲药业获盐酸多巴胺注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2479719207","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479719207?lang=zh_cn&edition=full","pubTime":"2024-10-31 16:18","pubTimestamp":1730362701,"startTime":"0","endTime":"0","summary":"财中社10月31日电九洲药业（603456）发布公告称，其控股子公司南京康川济医药科技有限公司近日获得国家药监局核准签发的盐酸多巴胺注射液的《药品注册证书》。该药品的注册号为CYHS2301483，剂型为注射剂，规格为2.5ml：50mg，注册分类为化学药品3类。盐酸多巴胺注射液适用于心肌梗死、创伤等引起的休克综合征，研发投入约为450万元。2023年国内市场销售金额为2.72亿元。此次注册将使公司能够在国内市场生产和销售该药品，进一步丰富公司产品管线，提升市场竞争力，但短期内对公司业绩影响不大。文章来源：财中社原标题：九洲药业获盐酸多巴胺注射液注册证书","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031162928a2006f16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031162928a2006f16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2479877875","title":"九洲药业：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2479877875","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479877875?lang=zh_cn&edition=full","pubTime":"2024-10-31 15:54","pubTimestamp":1730361266,"startTime":"0","endTime":"0","summary":"每经AI快讯，九洲药业 10月31日晚间发布公告称，近日，浙江九洲药业股份有限公司控股子公司南京康川济医药科技有限公司收到国家药品监督管理局核准签发的盐酸多巴胺注射液的《药品注册证书》。产品名称为“盐酸多巴胺注射液”。九洲药业的董事长是花莉蓉，女，56岁，学历背景为硕士；总经理是梅义将，男，49岁，学历背景为本科。截至发稿，九洲药业市值为147亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031155607ab899a79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031155607ab899a79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603456","BK0239","BK0070"],"gpt_icon":0},{"id":"2479720668","title":"九洲药业(603456.SH)子公司获盐酸多巴胺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2479720668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479720668?lang=zh_cn&edition=full","pubTime":"2024-10-31 15:43","pubTimestamp":1730360602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，公司控股子公司南京康川济医药科技有限公司(简称“康川济医药”)收到国家药品监督管理局核准签发的盐酸多巴胺注射液的《药品注册证书》(受理号：CYHS2301483)。盐酸多巴胺注射液，适用于心肌梗死、创伤、内毒素败血症、心脏手术、肾功能衰竭、充血性心力衰竭等引起的休克综合征;补充血容量后休克仍不能纠正者，尤其有少尿及周围血管阻力正常或较低的休克。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2479713521","title":"九洲药业大幅上涨 获主力净流入2077万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479713521","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479713521?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:34","pubTimestamp":1730338477,"startTime":"0","endTime":"0","summary":"10月31日，九洲药业股价大幅上涨，截至09点34分，九洲药业上涨5.35%，报16.34元/股，成交9075万元，换手率0.63%，振幅3.22%。资金动向截止发稿，九洲药业获得主力净流入2077万元，其中超大单流入1683万元，大单流入394万元。主营业务及业绩九洲药业公司主营业务为化学原料药及医药中间体的研发、生产与销售。最新财报显示，今年三季报，九洲药业实现营业收入39.65亿元，同比减少13.36%，净利润为6.31亿元，同比减少34.74%，基本每股收益为0.70元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031093455a1fe0ebf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031093455a1fe0ebf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2479982412","title":"【机构调研记录】金信基金调研伊之密、九洲药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2479982412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479982412?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:06","pubTimestamp":1730246796,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为金信智能中国2025混合A，最新单位净值为1.88，近一年增长26.9%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603456","300415","BK0239","BK0070","BK0251"],"gpt_icon":0},{"id":"2479329822","title":"【机构调研记录】国联基金调研伊之密、九洲药业等9只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479329822","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479329822?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:04","pubTimestamp":1730246649,"startTime":"0","endTime":"0","summary":"6）恒玄科技 个股亮点：公司主营产品包括TWS耳机芯片。旗下最近一年表现最佳的公募基金产品为国联高股息混合A，最新单位净值为1.08，近一年增长18.31%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300415","BK0239","BK0070","BK0186","BK0251","603456"],"gpt_icon":0},{"id":"2479515475","title":"九洲药业：10月25日接受机构调研，包括知名机构星石投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479515475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479515475?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:43","pubTimestamp":1730194981,"startTime":"0","endTime":"0","summary":"2024年前三季度，公司实现营业收入39.65亿元，同比减少13.36%，归属于母公司的净利润为6.31亿元，同比减少34.74%。公司第三季度的订单延期上半年的良好态势。特色原料药板块受市场竞争加剧影响，特别抗感染产品的价格波动较大，导致原料药业务三季度营收和毛利下滑较大，对公司整体营收带来负面影响。该股最近90天内共有13家机构给出评级，买入评级10家，增持评级3家；过去90天内机构目标均价为19.27。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900033954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2478947319","title":"开源证券：给予九洲药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478947319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478947319?lang=zh_cn&edition=full","pubTime":"2024-10-26 17:15","pubTimestamp":1729934118,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,汪晋近期对九洲药业进行研究并发布了研究报告《公司信息更新报告：Q3业绩阶段性承压，积极推进新业务领域布局》，本报告对九洲药业给出买入评级，当前股价为15.84元。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级8家，增持评级3家；过去90天内机构目标均价为15.6。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600008704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","603456"],"gpt_icon":0},{"id":"2478923319","title":"九洲药业：Q3业绩阶段性承压 积极推进新业务领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2478923319","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478923319?lang=zh_cn&edition=full","pubTime":"2024-10-26 00:00","pubTimestamp":1729872000,"startTime":"0","endTime":"0","summary":"业绩阶段性承压，新兴业务领域快速发展有望贡献新增量2024Q1-3，公司实现营业收入39.65 亿元，同比下滑13.36%；归母净利润6.31亿元，同比下滑34.74%；扣非归母净利润6.18 亿元，同比下滑-35.04%。正式成立TIDES 事业部，加速建设新兴业务领域2024 上半年，公司正式成立TIDES 事业部，多肽偶联药物技术平台获得快速扩张；公司目前已完成多肽平台和产能的布局规划，未来几年GMP 产能将获得快速提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410261831439f58bbe2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410261831439f58bbe2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2478167204","title":"九洲药业最新公告：公司通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2478167204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478167204?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:22","pubTimestamp":1729844543,"startTime":"0","endTime":"0","summary":"九洲药业公告，公司外沙厂区于2024年8月19日至8月23日期间接受了美国FDA的cGMP现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日，公司收到美国FDA签发的现场检查报告，该报告表明公司外沙厂区已通过本次cGMP现场检查。本次通过美国FDA现场检查，表明公司外沙厂区在药品cGMP管理体系和生产环境设施等方面符合美国FDA要求，为公司持续拓展国际市场提供了坚实的保障，并对拓展全球规范市场带来积极影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500026614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"gpt_icon":0},{"id":"2478672491","title":"10月25日九洲药业涨5.60%，招商创新增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2478672491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478672491?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:11","pubTimestamp":1729843913,"startTime":"0","endTime":"0","summary":"证券之星消息，10月25日九洲药业涨5.60%，收盘报15.84元，换手率5.13%，成交量46.06万手，成交额7.15亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为招商创新增长混合A。招商创新增长混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500026229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2478724656","title":"九洲药业涨5.60%，长城国瑞证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2478724656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478724656?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:11","pubTimestamp":1729843906,"startTime":"0","endTime":"0","summary":"今日九洲药业（603456）涨5.60%，收盘报15.84元。2024年8月29日，长城国瑞证券研究员胡晨曦发布了对九洲药业的研报《CDMO新增项目数可观，多肽与偶联业务进展顺利》，该研报对九洲药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为78.53%。此外，国联证券研究员郑薇，民生证券研究员王班,乔波耀近期也对该股发布了研报，同样给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为长江证券的方程嫣。九洲药业（603456）个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500026227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","161027"],"gpt_icon":0},{"id":"2478679848","title":"九洲药业(603456.SH)：通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2478679848","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478679848?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:32","pubTimestamp":1729841558,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，公司外沙厂区于2024年8月19日至2024年8月23日期间接受了美国食品药品监督管理局(简称“FDA”)的cGMP(现行药品生产质量管理规范)现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日，公司收到美国FDA签发的现场检查报告(EIR，Establishment Inspection Report)，该报告表明公司外沙厂区已通过本次cGMP现场检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603456","BK0070"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-10-10","address":"浙江省台州市椒江区外沙路99号","stockEarnings":[{"period":"1week","weight":-0.089},{"period":"1month","weight":0.0066},{"period":"3month","weight":0.1799},{"period":"6month","weight":-0.016},{"period":"1year","weight":-0.425},{"period":"ytd","weight":-0.3501}],"companyName":"浙江九洲药业股份有限公司","boardCode":"AI0027","perCapita":"18487股","boardName":"医药制造业","registeredCapital":"89523万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　浙江九洲药业股份有限公司主营业务为医药定制研发和生产（CDMO）服务，包含小分子化学药物、多肽药物、偶联药物和小核酸药物。公司产品涵盖合同定制类、抗感染类、中枢神经类药物、非甾体类药物、降血糖类药。公司获得中国医药工业百强企业、中国医药工业最具成长力企业、中国医药上市公司最具竞争力20强、第九届浙江省人民政府质量管理创新奖等多项荣誉。","serverTime":1731993666775,"listedPrice":15.43,"stockholders":"48424人(较上一季度减少0.66%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九洲药业,603456,九洲药业股票,九洲药业股票老虎,九洲药业股票老虎国际,九洲药业行情,九洲药业股票行情,九洲药业股价,九洲药业股市,九洲药业股票价格,九洲药业股票交易,九洲药业股票购买,九洲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}